


The Fund's investment objective is to provide an above average yield together with capital growth by investing predominantly in the UK.
| Name | % Net Assets | 
|---|---|
| GlaxoSmithKline | 6.7% | 
| Vodafone Group | 5.7% | 
| Royal Dutch Shell B | 5.3% | 
| British American Tobacco | 4.9% | 
| BP | 4.3% | 
| AstraZeneca | 3.6% | 
| Imperial Tobacco Group | 3.3% | 
| Unilever | 3.1% | 
| Aberforth UK Small Companies | 2.5% | 
| Reckitt Benckiser Group | 2.4% | 
| Key | % Net Assets | 
|---|---|
| 6.7% | |
| 5.7% | |
| 5.3% | |
| 4.9% | |
| 77.4% | 
| Date | 20-Aug-2025 | 
|---|---|
| NAV | 902.80p | 
| Currency | GBP | 
| Change | 1.00p | 
| % | 0.11% | 
| YTD change | 101.60p | 
| YTD % | 12.68% | 
| Fund Inception | 16/07/1975 | 
|---|---|
| Fund Manager | HSBC Multimanager | 
| TER | 1.65 (15-Jan-2012) | 
| Minimum Investment | |
|---|---|
| Initial | £1000 | 
| Additional | £500 | 
| Savings | £50 | 
| Charges | |
|---|---|
| Initial | 4.00% | 
| Annual Mang't | 1.50% | 
| Exit | n/a | 
| Name | % | 
|---|---|
| Standard deviation | 0.01 | 
| Sharpe ratio | 0.06 | 
You are here: research